Evommune is a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria (“CSU”), atopic dermatitis (“AD”) and ulcerative colitis (“UC”). Chronic inflammation is a significant healthcare problem in the world, substantially impacting patients’ quality of life and leading to life-threatening conditions. These conditions, if not prevented, ultimately lead to fatal diseases, such as cardiovascular diseases, diabetes and cancer, which contribute to three out of every five deaths worldwide and result in an estimated $90 billion of annual cost to the healthcare system in the United States. Our mission is to improve patients’ daily lives and prevent the long-term effects of uncontrolled inflammation that are a consequence of the limitations of existing therapies. To achieve this, we are advancing a portfolio of differentiated product candidates that target key drivers of chronic inflammation. Our management team’s proven drug development expertise and experience in the field of immunology and inflammation, combined with advanced scientific tools, enable us to identify and advance potent, highly selective molecules with distinctive mechanisms of action. By identifying treatment gaps of chronic inflammatory diseases, we strive to transform the treatment landscape, developing therapies that have the potential to offer rapid symptom relief and provide safe, durable resolution of the underlying disease. Among our portfolio of programs, we currently have two product candidates, EVO756 and EVO301, in Phase 2 trials. We are initially developing EVO756 for the treatment of CSU and AD, and EVO301 for the treatment of AD and UC. We see broad expansion potential for both programs across additional chronic inflammatory diseases. We also intend to advance additional preclinical programs into clinical development. Our most advanced clinical-stage product candidate, EVO756, is a potent and highly selective oral small molecule antagonist of MRGPRX2, a receptor predominantly found on mast cells and peripheral sensory neurons. We conducted a Phase 1 proof-of-concept trial in 132 healthy volunteers designed to assess the safety, tolerability, pharmacokinetic (“PK”) properties and pharmacodynamic (“PD”) properties of orally administered EVO756. EVO756 was observed to be well-tolerated at all doses tested, with no serious adverse events (“SAEs”), and PK results supporting daily dosing. As part of the trial, we conducted a skin challenge test in which EVO756 was observed to robustly decrease the healthy volunteers’ wheals induced by a MRGPRX2 ligand (“icatibant”), evidencing meaningful target engagement at all doses tested. We are currently conducting a Phase 2b trial of EVO756 in CSU and have completed a Phase 2 trial of EVO756 in chronic inducible urticaria (“CIndU”, and together with CSU, chronic urticarias or “CU”). Our CIndU Phase 2 trial was completed in May 2025 and generated data that demonstrated clinical activity (including improvement in FricTest score and pruritus numerical rating score (“pruritus-NRS”), as described below) in a patient population with symptomatic dermographism. Given significant overlap between the diseases and patient populations along with the contribution of neurogenic inflammation, we believe this supports the continued advancement of our CSU program. In addition, we believe EVO756’s clinical activity in symptomatic dermographism patients strongly supports the role of MRGPRX2 in neurogenic inflammation and supports the initiation of our AD program, as neurogenic inflammation plays a crucial role in both symptomatic dermographism and AD. In our Phase 2 CIndU trial, 70% (n=19) of the 27 observed patients demonstrated improvement at just four weeks, with 30% (n=8) of the observed patients achieving a complete response (achieving a FricTest score of zero (a clinician rated measure of symptomatic dermographism severity ranging from 0 to 4, with higher scores indicating greater severity)), of which 50% were immunoglobulin E (“IgE”) high (as defined by a serum IgE level of ≥100 IU/mL). An additional 11% (n=3) achieved a partial response as defined by a ≥2-point decrease in FricTest score and a further 30% (n=8) demonstrated a one-point decrease in FricTest score. Observed patients in the 300 mg once daily (“QD”) cohort saw an average reduction of 1.4 points in FricTest score after four weeks and observed patients in the 50 mg twice daily (“BID”) cohort saw an average reduction of 1.5 points. By comparison, in separate, independent trials conducted by third parties, patients treated with 300 mg omalizumab (n=19) saw a reduction of 1.4 points and patients treated with 300 mg barzolvolimab (n=33) saw a reduction of 1.6 points in FricTest score after four weeks. In addition, in our Phase 2 CIndU trial, both the 300 mg QD and the 50 mg BID doses of EVO756 were observed to result in rapid itch relief to patients, with observed patients in the 300 mg QD cohort experiencing an average reduction in pruritus-NRS of 2.4 points and observed patients in the 50 mg BID cohort seeing an average reduction of 2.1 points. Importantly, 93% (n=25) of observed patients demonstrated improvement at just four weeks in either FricTest or pruritus-NRS. Further, 75% (n=6) of those who did not achieve a decrease in FricTest score demonstrated a decrease in pruritus-NRS, evidencing the impact of EVO756 on itch at this early time-point, even in the absence of FricTest response. We initiated a Phase 2b dose-ranging trial in CSU in April 2025 and expect to report initial results in the first half of 2026. We also initiated a Phase 2b dose-ranging trial in moderate-to-severe AD patients in August 2025 and expect to report initial results in the second half of 2026. We plan to evaluate EVO756 in additional indications in which mast cell degranulation and neuroinflammation are key drivers of disease. Our second clinical-stage product candidate, EVO301, is a long-acting fusion protein consisting of an IL-18 binding protein (“BP”) and an anti-serum albumin Fab-associated (“SAFA”) domain. IL-18 is a pro-inflammatory cytokine of the IL-1 family that regulates various immune processes that drive inflammation and is a potent modulator of ongoing inflammation. We believe EVO301’s optimized approach to IL-18 binding and neutralization could enable significant advantages and differentiated clinical outcomes for patients, including with respect to efficacy, tissue distribution, dosing profile and reduced immunogenicity risk. In addition, EVO301’s distinct mechanism and modality complement those of EVO756, providing us with multiple potential avenues to bring innovative therapeutics to the large, underserved and rapidly expanding patient population suffering from chronic inflammatory diseases. We initiated a Phase 2 trial of EVO301 in adult patients with moderate-to-severe AD in March 2025 and expect to report initial results in the first half of 2026. Beyond AD, we plan to initiate a Phase 2 trial in moderate-to-severe UC patients in 2026. After completion of this UC trial, we may also evaluate EVO301 in Crohn’s disease and additional indications for which regulating the IL-18 pathway may reduce pro-inflammatory mediators driving tissue damage and chronic inflammation. Our principal executive offices are located in Palo Alto, CA.
AI Generated Analysis | Feedback
Here are 1-3 brief analogies to describe Evommune (EVMN):
- A **clinical-stage Regeneron**, but entirely focused on developing new drugs for autoimmune and inflammatory diseases.
- Like a **very early-stage AbbVie**, dedicated solely to discovering and developing novel treatments for inflammatory conditions.
AI Generated Analysis | Feedback
- IMU-935 (Povarlectin): An oral, small molecule, selective RORγt inhibitor in clinical development for autoimmune diseases such as psoriasis and atopic dermatitis.
- IMU-856: An oral DHODH inhibitor in preclinical development aimed at treating inflammatory bowel disease (IBD).
AI Generated Analysis | Feedback
Evommune (EVMN) is a clinical-stage biotechnology company focused on the discovery and development of novel immunomodulatory therapeutics. As a company in this stage of development, it does not currently have commercialized products or major customers that purchase its products or services in the traditional sense.
The company's primary activities involve research, development, and clinical testing of its drug candidates. Revenue for clinical-stage biotechnology companies typically comes from sources such as grants, collaborations, licensing agreements for drug candidates, or equity financing, rather than from the direct sale of products to other companies or individuals.
If and when Evommune's drug candidates successfully complete clinical trials and receive regulatory approval, they would then be commercialized. At that future point, the "customers" could be either:
- Other pharmaceutical companies (B2B) that license or acquire the rights to the approved drugs for broader commercialization and distribution.
- Ultimately, individual patients (B2C) through healthcare providers and pharmacies, who would benefit from the treatments. However, these are not direct customers of Evommune at its current stage.
Therefore, Evommune does not currently have identifiable major customers as it is not selling products or services in the market.
AI Generated Analysis | Feedback
Aldevron, LLC
Catalent Pharma Solutions, Inc. (CTLT)
AI Generated Analysis | Feedback
Luis Peña, President & Chief Executive Officer
Luis Peña is a Co-Founder of Evommune and has over 30 years of experience in biotech and pharmaceuticals. He co-founded Dermira Inc. in August 2010 and served as its Chief Development Officer, leading the R&D group through the company's sale to Eli Lilly & Company for $1.1 billion in 2020. Prior to Dermira, he held leadership roles at Stiefel (a GSK company), Stiefel Laboratories (before its acquisition by GSK), Connetics, Theravance, and Genentech.
Kyle Carver, Chief Financial Officer
Kyle Carver joined Evommune as CFO in March 2022. Before Evommune, he served as Chief Accounting Officer at Kadmon, a Sanofi Company. At Kadmon, he oversaw financial and accounting operations, including its transition to a public company via a 2016 IPO, and contributed to deal-making activities, such as Kadmon's acquisition by Sanofi for $1.9 billion in November 2021. He helped raise over $500 million through offerings at Kadmon. Prior to Kadmon, he held a senior role at KPMG.
Eugene A. Bauer, M.D., Chief Medical Officer
Dr. Eugene A. Bauer is a Co-Founder of Evommune and its Chief Medical Officer. From 2010 to 2020, he was a Founder, Chief Medical Officer, and board member of Dermira, which was acquired by Eli Lilly and Company in early 2020. Before Dermira, Dr. Bauer was President and Chief Medical Officer of Peplin until its acquisition by LEO Pharma in 2009. He was also CEO of Neosil, a company acquired by Peplin in 2008. He co-founded and was a board member of Connetics Corp., a dermatology company acquired by Stiefel Laboratories in 2006. He has also served on the boards of Aevi Genomic Medicine and Kadmon (acquired by Sanofi).
Gregory S. Moss, Chief Business and Legal Officer
Gregory S. Moss serves as Chief Business and Legal Officer, Corporate Secretary, and Chief Compliance Officer of Evommune. Previously, he was Executive Vice President, General Counsel, Corporate Secretary, and Chief Compliance Officer at Kadmon, where he led legal, compliance, and business development operations, culminating in Kadmon's $1.9 billion acquisition by Sanofi in 2021. During his decade-long tenure at Kadmon, he was a key strategic partner in financing activities, including its transition to a public company and helping raise over a billion dollars in debt and equity.
Janice Drew, Executive Vice President, Operations
Janice Drew is Executive Vice President, Operations at Evommune, bringing over 30 years of experience in clinical development. Prior to joining Evommune, Janice served as Senior Vice President, Portfolio Planning and Management at Dermira, Inc. for 10 years, where she supported clinical strategy, program development, and various operational functions. While at Dermira, she supported Phase 3 development and BLA for Cimziane®, NDA for QBREXZA®, and the global Phase 3 program for lebrikizumab. She also held positions at Peplin, where she led the Phase 3 program and NDA for Picato®, and at Allergan, building the Phase 3 development team for BOTOX®.
AI Generated Analysis | Feedback
The clear emerging threat to Evommune (EVMN) is the advancement of Ventyx Biosciences' (VTYX) oral RORγt inhibitor, VTX958. VTX958 is a direct competitor to Evommune's lead candidate, IMU-935, which also targets RORγt. Ventyx has reported positive Phase 2 clinical trial results for VTX958 in psoriasis and psoriatic arthritis and appears to be further along in development for these indications. Should VTX958 continue its successful clinical progression and potentially reach the market sooner or demonstrate superior efficacy/safety, it would significantly threaten the market potential of IMU-935 by capturing market share within the same emerging drug class.
AI Generated Analysis | Feedback
Evommune (EVMN) is a clinical-stage biotechnology company focused on developing therapies for chronic inflammatory diseases, with its main product candidates, EVO756 and EVO301, targeting chronic spontaneous urticaria (CSU), atopic dermatitis (AD), and ulcerative colitis (UC).
The addressable markets for Evommune's main products and services are as follows:
- Atopic Dermatitis (AD): The global market for atopic dermatitis drugs was estimated at $17.6 billion in 2024 and is projected to reach nearly $29.9 billion by 2030.
- Chronic Spontaneous Urticaria (CSU): The global chronic spontaneous urticaria market size was valued at approximately $2.1 billion in 2023, and the U.S. market accounted for about $1.19 billion of that in 2023. Other estimates for the global market size include $779.28 million in 2024, projected to reach $1,541.41 million by 2032, and $2,105.6 million in 2024, expected to reach $4,139.5 million in 2033.
- Ulcerative Colitis (UC): The global ulcerative colitis market size was valued at approximately $8 billion in 2024 and is estimated to grow to $12.5 billion by 2033. Another report indicates the global market reached $10.56 billion in 2025 and is projected to climb to $13.21 billion by 2030. North America held a significant share, commanding 43.82% of the global revenue in 2024. The U.S. inflammatory bowel disease treatment market, which includes ulcerative colitis, was valued at $9.37 billion in 2022.
AI Generated Analysis | Feedback
Here are 3-5 expected drivers of future revenue growth for Evommune (EVMN) over the next 2-3 years:
-
Successful Advancement and Commercialization of Lead Product Candidates (EVO756 and EVO301): Evommune's primary revenue growth driver is the successful clinical development and eventual commercialization of its lead drug candidates. EVO756, an oral small-molecule inhibitor, is currently in Phase 2b trials for chronic spontaneous urticaria (CSU) and atopic dermatitis (AD), with data readouts anticipated in the first half and second half of 2026, respectively. The company's second key candidate, EVO301, an IL-18-targeted fusion protein, is in Phase 2 for atopic dermatitis, with results also expected in 2026. Positive trial outcomes and subsequent regulatory approvals would enable market entry and direct sales.
-
Expansion of Product Pipeline into Additional Indications: Evommune plans to broaden the applications of its existing pipeline drugs. For EVO756, there's potential expansion into other chronic inflammatory indications beyond CSU and AD, such as symptomatic dermographism. EVO301 is slated for future studies in ulcerative colitis and Crohn's disease following its initial focus on atopic dermatitis. Additionally, the company is exploring the potential resumption of development for its IRAK4 inhibitor, EVO101, for hidradenitis suppurativa, based on an investigator-initiated trial. These expansions into new, large disease markets could significantly increase the addressable patient population and future revenue.
-
Strategic Partnerships and Licensing Agreements: Evommune has already demonstrated a strategy of leveraging partnerships to expand its reach and pipeline. It has an existing partnership with Maruho for the development and commercialization of EVO756 in select Asian markets and licensed EVO301 from AprilBio. Future revenue growth could be driven by additional out-licensing deals for its assets or joint-development partnerships with larger pharmaceutical companies, as well as shared R&D funding through industry or academic alliances.
-
Leveraging its Immune-Modulation Platform: Evommune's overarching strategy involves becoming a "platform-based player in inflammation biology." The company is focused on discovering and developing innovative therapies that target key drivers of chronic inflammatory diseases. By advancing a broad pipeline of differentiated product candidates and modulating mast cell, sensory neuron, and T-cell activity, Evommune aims to continuously develop new products for unmet medical needs, leading to long-term revenue streams through future monetization of its immune-modulation platform for new disease indications.
AI Generated Analysis | Feedback
Share Issuance
- Evommune completed its Initial Public Offering (IPO) on November 5, 2025, listing on the NYSE under the ticker EVMN.
- The company sold 9,375,000 shares at an initial public offering price of $16.00 per share, raising approximately $150 million in gross proceeds.
- Underwriters were granted a 30-day option to purchase an additional 1,406,250 shares.
Inbound Investments
- Evommune has raised a total of $276 million over 5 funding rounds since its founding in 2020.
- The largest funding round was a Series C round for $115 million in October 2024, co-led by RA Capital Management and Sectoral Asset Management.
- Other significant funding rounds include a Series B round for $57.5 million in March 2023, and a Series A round for $83 million in August 2021.
Outbound Investments
- Evommune in-licensed a second clinical program targeting IL-18 from South Korea-based biotech AprilBio to broaden its pipeline.
Capital Expenditures
- Net Property, Plant & Equipment was $1.0 million in Q2 2025.
- Total assets for EVMN in Q2 2025 were $96.21 million.
